Paving the TRAIL to Anti-Fibrotic Therapy

Hepatology - United States
doi 10.1002/hep.28520
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Thrombin-Induced CCN2 Expression as a Target for Anti-Fibrotic Therapy in Scleroderma

Journal of Cell Communication and Signaling
BiochemistryCell BiologyMolecular Biology
2009English

Hepatoprotective and Anti-Fibrotic Agents: It's Time to Take the Next Step

Frontiers in Pharmacology
Pharmacology
2016English

Overexpression of Anti-Fibrotic Factors Ameliorates Anti-Fibrotic Properties of Wharton's Jelly Derived Mesenchymal Stem Cells Under Oxidative Damage

BioScience Trends
BiochemistryHealthMedicineGeneticsMolecular Biology
2019English

PARP-1 Regulates Resistance of Pancreatic Cancer to TRAIL Therapy

Clinical Cancer Research
Cancer ResearchOncology
2013English

Anti‐fibrotic Mechanisms of Angiotensin AT 2 ‐receptor Stimulation

Acta Physiologica
Physiology
2019English

Commentary: Anti-Fibrotic Agents in the Post-Operative Period: Friends or Foes?

Journal of Thoracic and Cardiovascular Surgery
Respiratory MedicinePulmonaryCardiovascular MedicineSurgeryCardiology
2019English

The Promising Role of Anti-Fibrotic Agent Halofuginone in Liver Fibrosis/Cirrhosis

2017English

Discovery of a Small Molecule Having Both Potent Anti-Fibrotic and Anti-Inflammatory Capabilities

2019English

Pirfenidone Anti-Fibrotic Effects Are Partially Mediated by the Inhibition of MUC1 Bioactivation

Oncotarget
Oncology
2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy